<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623998</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT-Sita</org_study_id>
    <nct_id>NCT02623998</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)</brief_title>
  <official_title>An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes,a
      short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal
      insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in
      achieving sustained diabetes remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 100 patients with
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week
      course of treatment with sitagliptin, metformin, insulin glargine and lifestyle therapy, or
      (b) standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In
      all participants with HbA1C &lt; 7.3% at the 12 week visit, glucose-lowering medications will be
      discontinued and participants will be encouraged to continue with lifestyle modifications and
      regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who meet criteria
      for hyperglycemic relapse after stopping drugs will receive standard glycemic management as
      informed by the current Canadian Diabetes Association clinical practice guidelines
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission in the experimental group compared to the control group</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Diabetes remission is defined as HbA1C&lt;6.5% off chronic diabetes drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of severe hypoglycemic episodes</measure>
    <time_frame>64 weeks of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>36 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-free normal glucose tolerance</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Normal glucose tolerance is defined as a FPG&lt;6.1 mmol/L and a 2-hour plasma glucose &lt;7.8 mmol/L on a 75 g OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>12, 24, 36 and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from baseline</measure>
    <time_frame>12, 24, 36 and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin/metformin</intervention_name>
    <description>Dose is titrated to 50/1000 mg bid or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Janumet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive;

          2. type 2 diabetes mellitus diagnosed by a physician within 5 years prior to patient
             enrollment;

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization;

          4. HbA1C ≤ 9.5% on no oral hypoglycemic agents or HbA1C ≤ 8.0% on 1 oral agent or on
             half-maximal doses of 2 agents;

          5. body mass index ≥ 23 kg/m2;

          6. a negative pregnancy test and an agreement to use a reliable method of birth control
             for the duration of the trial in all females with childbearing potential;

          7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);
             ability and willingness to self-inject insulin;

          8. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin;

          2. history of hypoglycemia unawareness; history of severe hypoglycemia requiring
             assistance within the last 5 years;

          3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l;

          4. history of lactic acidosis or diabetic ketoacidosis;

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment;

          6. history of pancreatitis;

          7. cardiovascular disease including any of: a) systolic blood pressure &gt; 180 mmHg or
             diastolic blood pressure &gt; 105 mmHg; b) peripheral vascular disease; c) left bundle
             branch block or second or third degree AV block; d) tachyarrhythmias or
             bradyarrhythmias with uncontrolled ventricular rate; e) stenotic valvular heart
             disease; f) cardiomyopathy; g) history of heart failure; h) history of aortic
             dissection; i) documented history of angina or coronary artery disease; j) history of
             stroke or transient ischemic attack;

          8. history of any disease requiring continuous systemic glucocorticoid treatment;

          9. history of any major illness with a life expectancy of &lt; 3 years;

         10. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity;

         11. excessive alcohol consumption (&gt;14 alcoholic drinks per week in men and &gt;7 alcoholic
             drinks per week in women);

         12. known hypersensitivity to insulin glargine, metformin, or any DPP-4 inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia McInnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel C Gerstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia McInnes, MD</last_name>
    <email>natalia.mcinnes@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Sigal, MD</last_name>
      <phone>403-955-8107</phone>
      <email>rsigal@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Berard, RN</last_name>
      <phone>204-789-3228</phone>
      <email>LBerard@exchange.hsc.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Hramiak, MD</last_name>
      <phone>519-646-6353</phone>
      <email>Irene.Hramiak@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Gupta, MD</last_name>
      <phone>905-294-0800</phone>
      <email>markhamresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univeristy of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Remi Rabasa-Lhoret, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <keyword>Metformin</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Diet</keyword>
  <keyword>Excercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

